Aldeyra Therapeutics (ALDX.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -$0.14, previous value of -$0.27, expected value of -$0.14.

Aldeyra Therapeutics (ALDX.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -$0.14, previous value of -$0.27, expected value of -$0.14.

Zhitong FinanceMay 3 16:20

Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR), Dexcom (DXCM) and Aldeyra Therapeutics (ALDX)

TipRanksApr 30 15:31

Aldeyra Therapeutics Unveils R&D Progress and Goals

TipRanksApr 25 19:13

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa.

BusinesswireApr 25 19:00

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024

PDF Version LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 18, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the tr

Aldeyra TherapeuticsApr 18 12:00

Aldeyra Therapeutics(ALDX.US) 10% Shareholder Buys US$833.87K in Common Stock

$Aldeyra Therapeutics(ALDX.US)$ 10% Shareholder PERCEPTIVE ADVISORS LLC purchased 177.99K shares of common stock on Apr 4, 5, 2024 at an average price of $4.68 for a total value of $833.87K. This tran

Futu NewsApr 9 06:12